Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
116 hedge funds and large institutions have $1.16B invested in Global Blood Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 41 increasing their positions, 25 reducing their positions, and 19 closing their positions.
215% more capital invested
Capital invested by funds: $367M → $1.16B (+$788M)
137% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 19
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
64% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 25
42% more call options, than puts
Call options by funds: $19M | Put options by funds: $13.4M
21% more funds holding
Funds holding: 96 → 116 (+20)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$64.6M |
| 2 |
WSC
White Square Capital
London,
United Kingdom
|
+$36.6M |
| 3 |
O
OrbiMed
New York
|
+$27.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.3M |
| 5 |
PA
Perceptive Advisors
New York
|
+$18.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$19.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$17.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$10.5M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$6.73M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$5.61M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAM
126
Aberdeen Asset Management
Aberdeen,
United Kingdom
| – | -$669K | -46,293 | Closed |
|
|
SIM
127
Spark Investment Management
New York
| – | -$419K | -29,000 | Closed |
|
128
Bessemer Group
Woodbridge,
New Jersey
| – | -$335K | -23,160 | Closed |
|
|
HTC
129
Hershey Trust Company
Hershey,
Pennsylvania
| – | -$317K | -21,944 | Closed |
|
|
HLA
130
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$211K | -14,628 | Closed |
|
|
RFCA
131
R&F Capital Advisors
New York
| – | -$148K | -10,219 | Closed |
|
132
Simplex Trading
Chicago,
Illinois
| – | -$104K | -4,131 | Closed |
|
|
CCM
133
Cribstone Capital Management
Augusta,
Maine
| – | -$56K | -3,328 | Closed |
|
|
SIG
134
Stanford Investment Group
Mountain View,
California
| – | -$20K | -1,400 | Closed |
|
|
NIT
135
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$13K | -900 | Closed |
|
|
TRCT
136
Tower Research Capital (TRC)
New York
| – | -$3K | -200 | Closed |
|
GBT Hedge Fund Activity: Q1 2017 in Review
116 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2017, worth a combined $1.16B — up 215% from $367M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new GBT positions and 19 closed out — a net gain of 26 holders — while 41 added to existing stakes and 25 trimmed.
The largest buyer was BlackRock, adding an estimated $64.6M. The largest seller was Sectoral Asset Management, cutting an estimated $19.7M.
- 116 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2017, up from 96 in Q4 2016.
- Funds reported $1.16B of Global Blood Therapeutics, Inc. stock for Q1 2017, up 215% quarter-over-quarter.
- 45 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2017 and 19 closed out, a net change of +26 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $64.6M added.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2017 was Sectoral Asset Management, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2017.